KRAS and lung adenocarcinoma: The novel combination of the epigenetic gene ASF1, a histone H3-H4 chaperone, and anti-PD1 immunotherapy for KRAS-mutant lung adenocarcinoma patients has been described by Li at al. after performing a custom epigenetic-focused CRISPR/Cas9 in vivo screen using a KRASG12C/Trp53−/− mouse model [126].